Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer

SIMPLE SUMMARY: Immunotherapy is currently the backbone of new drug treatments for many cancer patients. CXC chemokine ligand 13 (CXCL13) is an important factor involved in recruiting immune cells that express CXC chemokine receptor type 5 (CXCR5) in the tumor microenvironment and serves as a key mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ching-Hung, Jian, Cheng-Zhe, Lin, Liang-In, Low, Guan-Sian, Ou, Ping-Yun, Hsu, Chiun, Ou, Da-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774093/
https://www.ncbi.nlm.nih.gov/pubmed/35053457
http://dx.doi.org/10.3390/cancers14020294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774093/
https://www.ncbi.nlm.nih.gov/pubmed/35053457
http://dx.doi.org/10.3390/cancers14020294

Ejemplares similares